How big is the India CMO Market?

The India CMO Market size is expected to reach USD 22.51 billion in 2024 and grow at a CAGR of 14.67% to reach USD 44.63 billion by 2029. Read More

What is the current India CMO Market size?

In 2024, the India CMO Market size is expected to reach USD 22.51 billion. Read More

Who are the key players in India CMO Market?

Dr. Reddy’s Laboratories, Cadila Healthcare Limited, MSN Laboratories Pvt Ltd, Cipla Ltd. and Akums Drugs and Pharmaceuticals Limited are the major companies operating in the India CMO Market. Read More

What years does this India CMO Market cover, and what was the market size in 2023?

In 2023, the India CMO Market size was estimated at USD 19.63 billion. The report covers the India CMO Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the India CMO Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

India CMO Market Analysis | Industry Report, Size & Forecast Overview

Contract Manufacturing in India Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The report covers Top Contract Manufacturing Companies in India and the market is segmented by Service Type (API and Intermediates, Finished Dose). The market sizes and forecasts are provided in terms of value (USD million) for all the above segments.

India CMO Industry Overview

The India Contract Manufacturing Organization (CMO) market is fragmented, with the top vendors accounting for a significant share of the total market. Apart from these major players, several players in the market are investing in innovation and partnership activities to gain an increased market share. Therefore, the intensity of competitive rivalry is high. The key players are Dr. Reddy's Laboratories, Cadila Healthcare Limited, Cipla Ltd., etc. Recent developments in the market are -

In July of 2022, Cipla Limited reported that Endura Mass, a well-known nutritional supplement brand in the weight gain category from Medinnbelle Herbalcare Private Limited, was acquired by Cipla Health Limited (CHL), a wholly owned subsidiary and consumer healthcare arm of the company.

In May 2022, The South Korean company HK inno. N Corporation and the Indian company Dr. Reddy's Laboratories formed an exclusive partnership for the supply and commercialization of HK inno.N Corporation's patented novel molecule Tegoprazan for gastrointestinal diseases in India and six important Emerging Markets.